Penetrating Noise, Directing Signal: 'Frost & Sullivan Business Insights Review', October 2026 Issue

Dispute over Revenue Recognition between OpenAI and Anthropic:The difference between gross and net, revealing the computing power costs and channel dependence behind the high-growth trajectory of model companies. When cloud providers act as investors, suppliers, and distributors, the revenue size is insufficient to explain the enterprise's value. Whether a trillion-dollar valuation is valid ultimately depends on whether unit costs can decrease and whether cash flows can cover long-term computing power commitments.

The First Remote Robot Surgery in West Africa:Xinglian Main Chain, Tumai Going Global: Remote surgery has opened up a new market for Chinese medical equipment and made the communication link a key condition for going global. While the equipment can be exported, network coverage is determined by external operators. The long-term barrier will come from the sustained delivery capability supported by reliable communication, local physician training, and regulatory access.

Commercialization of Nuclear Fusion:Newly Added Electricity, or Energy Shuffle: Grid connection applications and power purchase agreements are bringing nuclear fusion into enterprises' long-term energy planning. However, the signed capacity still lags behind actual supply. Only when low-carbon electricity with competitive prices is continuously delivered and the user purchase and power source competition relationship is changed can nuclear fusion move from new supply to reshaping the energy landscape.

From the Price Cut Era to Innovative Payment:How Commercial Health Insurance Is Reshaping the Commercialization of Innovative Drugs: Commercial insurance is opening up payment space for high-value innovative therapies and also driving further differentiation among innovative drug companies. Clinical value and access capability will jointly determine commercial returns. The inclusion in the table of contents is just the beginning; coverage scope, renewal stability, and payout efficiency determine whether the payment commitment can turn into genuine demand.

The World's First mRNA Cancer Vaccine Phase III Clinically Successfully Completed, and Tumor Vaccines Are About to Subvert the History of Anti-Cancer Therapy:Personalized tumor vaccines open a new path for post-surgical recurrence prevention and push industrial competition toward novel antigen prediction, customized production, and delivery efficiency. Whether clinical breakthroughs can translate into commercial returns remains dependent on indication expansion and cost reduction. Moving from an effective therapy to widespread accessibility is still a long journey.

Redio's First Nuclear Medicine Drug:China's Global Definition Rights in the Sub-segment of Nuclear Medicine Imaging: The value of the original imaging drug also lies in expanding the application space for existing SPECT devices. The differentiated probe is expected to balance diagnostic capability and affordability, opening up a new path for domestic nuclear medicine drugs. Value realization still requires hospital access, radionuclide supply, and clinical promotion in coordination, and gradually extend to integrated diagnosis and treatment.